| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Bisoctrizole targets UV radiation by absorbing both UVA and UVB rays and converting them into less harmful energy. It also reflects and scatters UV light due to its microfine structure. The compound does not target a specific biological receptor but provides photoprotection by preventing UV radiation from reaching the skin's viable layers. Its mechanism of action is physical (scattering) and chemical (absorption).
|
|---|---|
| ln Vitro |
In vitro, bisoctrizole is a potent UV-absorbing agent that can absorb both UVA and UVB radiation. It exhibits excellent photostability and minimal skin penetration. The compound's UV absorption spectrum covers a broad range, making it effective for full-spectrum sun protection. Its microfine structure also causes light scattering and reflection.
|
| ln Vivo |
In vivo, bisoctrizole is used as an active ingredient in sunscreen products to prevent sunburn and skin damage caused by UV radiation. Its minimal skin penetration ensures that it remains on the skin surface, providing effective protection without systemic absorption. Clinical studies have demonstrated its efficacy and safety in sunscreen formulations.
|
| Enzyme Assay |
For in vitro UV absorption assays, bisoctrizole is evaluated by measuring its absorbance spectrum using a UV-Vis spectrophotometer. The compound is dissolved in a suitable solvent (typically ethanol or DMSO) and scanned from 200-400 nm. The absorbance maxima and extinction coefficients are determined. Photostability is assessed by exposing the compound to UV radiation and measuring the change in absorbance over time.
|
| Cell Assay |
For in vitro cell-based assays, bisoctrizole is tested on skin cells such as keratinocytes or fibroblasts to evaluate its photoprotective effects. Cells are treated with the compound (typically 0.1-10 µg/mL) and exposed to UV radiation. Cell viability is assessed using MTT assays. DNA damage is measured by quantifying cyclobutane pyrimidine dimers or 8-oxo-dG. Inflammatory cytokine production is measured by ELISA.
|
| Animal Protocol |
For in vivo animal experiments, bisoctrizole is typically applied topically to the skin of mice or rats. The compound is formulated in a suitable vehicle and applied at doses of 1-10 mg/cm². Animals are then exposed to UV radiation. Skin redness (erythema), edema, and histopathological changes are assessed. The sun protection factor (SPF) is determined by comparing the minimal erythema dose between treated and untreated skin.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
An in vitro rat and human skin penetration study showed that bisoprezol is minimally absorbed through the skin, with only approximately 0.01% and 0.06% of the administered dose, respectively, permeating the skin membranes of humans and rats. Despite the low skin absorption rate, bioaccumulation following repeated skin administration cannot be ruled out. No pharmacokinetic data. No pharmacokinetic data. No pharmacokinetic data. Metabolisms/Metabolites No pharmacokinetic data. Biological Half-Life No pharmacokinetic data. Pharmacokinetic data for bisoctrizole indicate minimal systemic absorption. The compound remains on the skin surface and is not significantly absorbed into the circulation. Its molecular weight is 658.87 g/mol and formula is C₄₁H₅₀N₆O₂. Due to its large size and lipophilicity, it does not penetrate the stratum corneum effectively, ensuring its safety for topical use. |
| Toxicity/Toxicokinetics |
Protein Binding
No pharmacokinetic data available. Toxicological data for bisoctrizole indicate that it is safe for use in sunscreens at concentrations up to 10%. It is not a skin sensitizer or irritant. The compound has not shown systemic toxicity in animal studies due to its minimal absorption. It is approved for use as a UV filter in sunscreens in many countries, including the EU and Australia. |
| References |
[1]. Effect of Bisoctrizole on Ultraviolet (UV) Absorption Properties of Silicone and Effect on Surface Roughness-An In Vitro Study. Indian J Dent Res. 2024 Apr 1;35(2):211-215.
[2]. Vaccinium myrtillus L. extract associated with octocrylene, bisoctrizole, and titanium dioxide: in vitro and in vivo tests to evaluate safety and efficacy. J Cosmet Dermatol. 2022 Oct;21(10):4765-4774. |
| Additional Infomation |
Bisoxatazole is a diarylmethane. Bisoxatazole, also known as methylenebisbenzotriazole tetramethylbutylphenol, is a broad-spectrum organic ultraviolet filter, marketed under the trade name Tinosorb M. It is an organic compound based on benzotriazole that absorbs, reflects, and scatters UV-A and UV-B rays. Bisoxatazole has not yet been approved by the U.S. Food and Drug Administration (FDA), but it is approved in the European Union and other parts of the world for use as an ultraviolet filter in sunscreens, day care products, and skin whitening products at a maximum concentration of 10%. Pharmacological Indications: Suitable as a sunscreen ingredient in cosmetics. Mechanism of Action: Bisoxatazole is an organic UVA filter that absorbs both UVA and UVB rays. Pharmacodynamics: Under in vitro androgen competitive binding assay conditions, bisoxatazole did not show intrinsic androgenic, estrogenic, or uterine-nourishing activity.
Bisoctrizole is approved for use as a UV filter in cosmetic products. It is marketed under the brand name Tinosorb M by BASF. Its molecular weight is 658.87, and its formula is C₄₁H₅₀N₆O₂. The compound is a broad-spectrum UV filter that absorbs UVA and UVB radiation and reflects and scatters UV light. It is available from various chemical suppliers for cosmetic formulation research. |
| Molecular Formula |
C41H50N6O2
|
|---|---|
| Molecular Weight |
658.8747
|
| Exact Mass |
658.399
|
| CAS # |
103597-45-1
|
| PubChem CID |
3571576
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
771.6±70.0 °C at 760 mmHg
|
| Melting Point |
197-199 °C(lit.)
|
| Flash Point |
420.5±35.7 °C
|
| Vapour Pressure |
0.0±2.7 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
14.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
49
|
| Complexity |
989
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C(=C([H])C(=C([H])C=1C([H])([H])C1=C(C(=C([H])C(=C1[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])N1N=C2C([H])=C([H])C([H])=C([H])C2=N1)O[H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])N1N=C2C([H])=C([H])C([H])=C([H])C2=N1
|
| InChi Key |
FQUNFJULCYSSOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C41H50N6O2/c1-38(2,3)24-40(7,8)28-20-26(36(48)34(22-28)46-42-30-15-11-12-16-31(30)43-46)19-27-21-29(41(9,10)25-39(4,5)6)23-35(37(27)49)47-44-32-17-13-14-18-33(32)45-47/h11-18,20-23,48-49H,19,24-25H2,1-10H3
|
| Chemical Name |
2-(benzotriazol-2-yl)-6-[[3-(benzotriazol-2-yl)-2-hydroxy-5-(2,4,4-trimethylpentan-2-yl)phenyl]methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol
|
| Synonyms |
Bisoctrizole; FAT 75'634; Bisoctrizole [USAN]; Bisoctrizol; 8NT850T0YS;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Acetone : 1 mg/mL (~1.5 mM)
DMSO : ~1 mg/mL (~1.5 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5178 mL | 7.5888 mL | 15.1775 mL | |
| 5 mM | 0.3036 mL | 1.5178 mL | 3.0355 mL | |
| 10 mM | 0.1518 mL | 0.7589 mL | 1.5178 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
